Journal article icon

Journal article

Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy

Abstract:

Programmed cell death ligand 1 (PD-L1) interacts with programmed cell death protein-1 (PD-1) as an immune checkpoint. Reactivating the immune response by inhibiting PD-L1 using therapeutic antibodies provides substantial clinical benefits in many, though not all, melanoma patients. However, transcriptional suppression of PD-L1 expression as an alternative therapeutic anti-melanoma strategy has not been exploited. Here we provide biochemical evidence demonstrating that ultraviolet radiation (U...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted Manuscript

Actions


Access Document


Files:
Publisher copy:
10.1038/s41388-018-0314-0

Authors


Expand authors...
More from this funder
Grant:
R01CA137098, R01CA193913 and R01CA196896
More from this funder
Grant:
Establish Investigator Award (RC)
Publisher:
Springer Nature Publisher's website
Journal:
Oncogene Journal website
Volume:
37
Pages:
4941–4954
Publication date:
2018-05-22
Acceptance date:
2018-04-20
DOI:
EISSN:
1476-5594
ISSN:
0950-9232
Pubs id:
pubs:846503
URN:
uri:d0985f16-1fd8-4bd3-8a63-26e8b0d45bee
UUID:
uuid:d0985f16-1fd8-4bd3-8a63-26e8b0d45bee
Local pid:
pubs:846503

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP